developments in pk/pd: optimising efficacy & prevention of resistance
DESCRIPTION
Developments in pK/pD: optimising efficacy & prevention of resistance A critical review of pK/pD in in vitro models Alasdair MacGowan Bristol Centre for Antimicrobial Research & Evaluation University of Bristol & North Bristol NHS Trust Southmead Hospital Bristol, UK. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/1.jpg)
1
Developments in pK/pD:
optimising efficacy & prevention of resistance
A critical review of pK/pD in in vitro models
Alasdair MacGowanBristol Centre for Antimicrobial Research & Evaluation
University of Bristol & North Bristol NHS TrustSouthmead Hospital
Bristol, UK
![Page 2: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/2.jpg)
2
OBJECTIVES OF STUDYING pK/pD IN IN VITRO MODELS
• tests of efficacy
determination of dominant pK/pD parameter
determination of the magnitude of the dominant pK/pD parameter
• emergence of resistance
• determination of dominant pK/pD parameter
• determination of the magnitude of the dominant pK/pDparameter
![Page 3: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/3.jpg)
3
TESTS OF EFFICACY
• human dosing or other
• activity of agent vs target pathogen co resistance's
• activity of agent and comparator(s) vs target pathogen
• activity of agent v target pathogen with various MICvalues of the agent
• activity of agent vs target pathogen with variousmechanisms of resistance to the agent
• activity of agent vs different bacterial species oftarget pathogen
![Page 4: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/4.jpg)
4
ACTIVITY AGAINST TARGET PATHOGENS
i.e. moxifloxacin 400mg 24hrly
species MIC50 strain log reduction (mg/L) MIC viable count
(mg/L) 24h
S pneumoniae 0.06 0.08 5.6 0.4H influenzae 0.03 0.06 6.5 0.2M catarrhalis 0.06 0.08 5.1 1.2
S aureus 0.06 0.06 2.4 1.1Group A strep 0.12 0.16 3.1 1.9
MacGowan, 1999; MacGowan et al, 1998;MacGowan et al, 1999a; MacGowan et al, 1999b
![Page 5: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/5.jpg)
5
ACTIVITY OF AGENT AND COMPARATOR AGAINST TARGET
agents target referencepathogen
trova/cipro S aureus Firsov et al, 1999trova/cipro S aureus O’Brien et al, 1999levo/cipro S pneumoniae Lister & Saunders, 1999
moxi/grepa/clari S aureus Esposito et al, 2000 Gp A streptococci
trova/gati/clina S pneumoniae Hershberger & Rybak, 2000spar/levo/cipro
moxi/levo/gati/cipro S pneumoniae Firsov et al, 2000 various
![Page 6: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/6.jpg)
6
ACTIVITY OF AGENTS AGAINST TARGET PATHOGENS WITH VARIOUS MICs - USUALLY INCREASING
gemifloxacin 320mg 24hrly vs S. pneumoniae (MIC50 0.015; MIC90
0.03/6mg/L)
Strains MIC log reduction in viable count (mg/L) 24h 48h
0.016 5.3 0.3 5.3 0.30.06 3.4 1.4 6.2 0.10.10 4.1 0.5 5.7 0.20.16 0.6 1.4 3.9 0.90.24 0.2 0.4 0.5 0.2
MacGowan et al, (in press)
![Page 7: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/7.jpg)
7
ACTIVITY OF AGENTS AGAINST PATHOGENS WITH DIFFERENTMECHANISM OF RESISTANCE (1)
S aureus with Nor A efflux pump
S aureus (Nor A expression induced)
log cfu/ml at 72h
levofloxacon 4.8 0.4levofloxacin + omeprazole 4.8 0.4ciprofloxacin 9.5 0.3ciprofloxacin + omeprazole 7.4 0.5
Aeschlimann et al, 1999
![Page 8: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/8.jpg)
8
ACTIVITY OF AGENTS AGAINST PATHOGEN WITH DIFFERENT MECHANISMS OF RESISTANCE (2)
gemifloxacin 320mg od, for 72hr log reduction time to kill
MIC count at 99.9%(mg/L) mechanism 72h (h)
0.06 none 5.3 0.3 26 2 efflux pump 5.8 0.3 15 12 gyr A mutation 1.2 0.3 > 72 par C mutation 1.2 0.3 > 72
0.12 efflux pump 3.8 21 8 gyr A mutation 0.4 0.4 > 72
![Page 9: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/9.jpg)
9
ACTIVITY AGAINST DIFFERENT TARGET PATHOGENS
i.e. moxifloxacin 400mg od vs S pneumoniae or P aeruginosa bothMIC 0.25mg/L
S pneumoniae P aeruginosa
log reduction count@ 24h 3.4 1.2 0.1 0.2@ 48h 4.2 1.0 0.7 0.5@ 72h 4.8 0.5 0.1 0.6
time to kill 99.9% (h) 16 7 >72
![Page 10: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/10.jpg)
10
CONCLUSIONS ON TESTS OF EFFICACY -
easy, descriptive, limited but useful information
![Page 11: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/11.jpg)
11
DETERMINATION OF DOMINANT pK/pD PARAMETER
dosing regimen employed(differentiation between AUC/MIC; Cmax/MIC;T > MIC)
end point chosen
analytic tools used
susceptibilities of target strains
effects of aggregation of data(i.e. species or mechanisms)
![Page 12: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/12.jpg)
12
PRODUCING VARIABILITY IN pK/pD PARAMETERS
dose escalation MIC differencesdose fractionation
ranges in pD/pK parameters(AUC/MIC; Cm/MIC; T > MIC)
![Page 13: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/13.jpg)
13
DOSING REGIMENS
dose conclusion
ciprofloxacin Cm 5mg/L AUC/MIC related toofloxacin 5mg/L, 8mg/L; outcomedifferent t/12 Madaras-kelly et al, 1996a
ofloxacin Cm 3.5-62mg/L AUC/MIC relatedciprofloxacin Cm 1.1-20mg/L to outcomeplus others Madaras-Kelly et al, 1996b
gemifloxacin AUC/MIC or T>MIC160mg bd; 320mg od; related to outcome640mg 48h Bowker et al, 2000
![Page 14: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/14.jpg)
14
GEMIFLOXACIN DOSE FRACTIONATION PLUSMIC RANGE 0.016 - 0.24mg/L
Spearman rankCorrelation (95% CI)
AUC/MIC v Cm/MIC 0.77 (0.42 - 0.92)AUC/MIC v T > MIC 0.87 (0.60 - 0.96)Cm/MIC v T > MIC 0.42 (0.14 - 0.77)
![Page 15: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/15.jpg)
15
END POINTS -
measures of antibacterial effect (ABE)
measures in time (X axis)time to kill 90, 99, 99.9 etctime to maximum kill
measures in viable count (Y axis)log kill at 12, 24, 36 etc h
log kill after dose (~)maximum kill
“integrated” measures (X and Y)slope of kill curveareas around the kill curve
![Page 16: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/16.jpg)
16
AREA MEASURES
log cfu/ml
control
IE
AUBC
test
timeAAC: area above the curveAUBC: area under the bacterial (kill) curve AUBKCIE: intensity of effect (area between curves, (log C - log T) xt)AUBKC (test) /AUBKC (control) ratio
AAC
![Page 17: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/17.jpg)
17
PERCENTAGE CO-EFFICIENTS OF VARIATION OF ANTIBACTERIAL EFFECT MEASURES
moxifloxacin 69 simulations number
of occasionsmeasure measurable % CV (median; range)
log change @ 12hr 15 32 (9 - 100) 24hr 13 55 (8 - 72)
36hr 10 25 (4 - 97)48hr 12 43 (6 - 132)
maximum log 12 17 (4 - 88)T99 17 25 (0 - 70)T99.9 17 27 (5 - 75)AUBKC24 21 14 (1 - 65)AUBKC48 21 14 (1 - 74
![Page 18: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/18.jpg)
18
EFFECT OF CHOSEN ANTIBACTERIAL EFFECTMEASURE ON DOMINANT pK/pD PARAMETER
gemifloxacin 160mg x 4 over 48 hr320mg x 2 over 48 hr640mg x 1 over 48 hr
five strains of S pneumoniae(MIC 0.016; 0.06; 0.1; 0.16; 0.24 mg/L)
pD parameters: AUC/MIC (72 - 1219) Cmax/MIC (3 - 131) T > MIC (38 - 100%)
![Page 19: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/19.jpg)
19
using Emax model
AUC/MIC related to AUBKC48 best Cmax/MIC and T>MIC less well
weighted least squares regression analysis
AUC/MIC and T>MIC predictors of AUBKC48
Cmax/MIC not predictive of AUBKC48
![Page 20: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/20.jpg)
20
Cox proportional hazards regression
- ABE: time to kill 99.9% inoculum
univariate analysis AUC/MIC, Cm/MIC and T > MIC relatedto T99.9
multivariate model
Cmax/MIC related to T99.9
Cm/MIC relative risk 95% CI <5 1.0 5 - 9.9 7.7 2.2 - 27.2 10 - 29.9 11.6 4.3 - 31.8 >30 20.7 2.3 - 68.3
![Page 21: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/21.jpg)
21
WHY AUC/MIC AND T > MIC PREDICT AUBKC48
log change count dosing regimen
MIC(mg/L) 160mg x 4 320mg x 2 640mg x 1
0.016 maximum - 5.2 - 5.3 - 4.8final - 4.8 - 5.3 - 4.8
0.06 maximum - 4.5 - 6.2 - 6.2final - 4.0 - 6.2 + 0.1
0.10 maximum - 6.6 - 5.7 - 6.2final - 5.2 - 3.9 0
0.16 maximum - 2.8 - 3.9 - 4.6final - 2.3 - 0.6 0
0.24 maximum - 3.3 - 0.5 - 4.7final - 0.8 + 0.3 + 0.3
![Page 22: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/22.jpg)
22
If exclude simulation with T > MIC of <70% thenAUC/MIC predicts AUBKC48 in multi variateanalysis
![Page 23: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/23.jpg)
23
COX PROPORTIONAL HAZARDS REGRESSIONANALYSIS FOR T99.9 AND REGROWTH
81 experiments with gemifloxacin and moxifloxacin againstS. pneumoniae
In 59/81 experiment T99.9 achieved
In 24/59 regrowth occurred
AUC/MIC, Cm/MIC and T > MIC related to both measures
T99.9 related to Cm/MIC especially > 5Regrowth related to T > MIC
AUC/MIC did not predict T99.9 or regrowth
![Page 24: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/24.jpg)
24
THEREFORE -
T99.9 Cm/MICslope
log cfu/ml
AUBKC AUC/MIC
RegrowthIE
T > MIC
![Page 25: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/25.jpg)
25
ANTIBACTERIAL EFFECT MEASURES
Strengths Weakness
T99.9 • easy to understand • highly variable • easy to measure • not always related to pD
• suitable for time to parameters event analysis • doesn’t capture
regrowth data
intensity of effect • less variable • depends on regrowth • strong comparative • T > MIC driven
(inter quinolone predictor) database • linear over a large • linear over therapeutic AUC/MIC range AUC/MIC range • AUC/MIC an
intra quinolone predictor i.e. FQ specific
![Page 26: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/26.jpg)
26
ANTIBACTERIAL EFFECT MEASURES
Strengths Weakness
area under curve • less variable • size-counter intuitive • AUC/MIC driven i.e. AUC/MIC 1/AUBKC • sigmoid relationship to AUC/MIC
![Page 27: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/27.jpg)
27
CONCLUSION - DETERMINATION OF Pd PARAMETER
end point matters
![Page 28: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/28.jpg)
28
DETERMINATION OF THE MAGNITUDE OF THEpK/pD PARAMETER
AUC/MIC for optimal outcome v S. pneumoniae (1)
AUC/MIC 30-55 sustained 4 log reduction with levofloxacinLacey et al, 1999a
AUC/MIC >45 sustained 5 log reduction with trovafloxacinand ofloxacin
Lister & Saunders, 1999b
AUC/MIC of 44 sustained 5 log reduction with levofloxacinLister & Saunders,
![Page 29: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/29.jpg)
29
AUC/MIC AND S. PNEUMONIAE (2)
AUC/MIC 50 = 60 for In AUBKC levofloxacin, ofloxacinciprofloxacin
Madaras - Kelly et al, 1997
AUC/MIC >250 for lowest AUBKC gemifloxacin
Bowker et al, 2000
AUC/MIC >250 for lowest AUBKC moxifloxacin
Bowker et al, 2001
![Page 30: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/30.jpg)
30
AUC/MIC and S. PNEUMONIAE (3)Moxifloxacindose MIC AUC/MIC clearance
(sustained 5 log reduction400 OD 0.08 375 Yes400 BD 0.25 320 Yes800 OD 0.25 320 Yes400 OD 0.12 167 No400 OD 0.25 160 No400 OD 1 30 No400 BD 4 20 No800 OD 4 20 No400 OD 2 15 No400 OD 4 10 NoGemifloxacin320 OD 0.016 625 Yes320 OD 0.06 166 No320 OD 0.10 100 No320 OD 0.16 62 No320 OD 0.25 41 No
![Page 31: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/31.jpg)
31
WHY THE DIFFERENCE?
inoculum
growth phase
total organisms exposed
![Page 32: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/32.jpg)
32
EFFECT OF INOCULUM ON IE; CIPROFLOXACINAND TROVAFLOXACIN
relative IE
S aureus E coli
8 log 1.05 1.12
6 log 0.98 (-7%) 0.92 (-18%)
from Fig 4, Firsov et al, 1999
![Page 33: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/33.jpg)
33
IS THE AUC/MIC THE SAME FOR DIFFERENT SPECIES?
Moxifloxacin AUBKC48 (log cfu/ml) MIC (mg/L) Gram + Gram -
0.1 95 44 33 15 0.1 - 0.5 170 65 63 14 > 0.5 240 30 99 21
Gram +; S pneumoniae, S aureus, GpA streptococciGram -; H influenzae, M catarrhalis
(MacGowan, 1999)
![Page 34: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/34.jpg)
34
IS THE AUC/MIC THE SAME FOR DIFFERENT SPECIES? (2)
AUC0-72/MIC for 50% effect
AUBKC 72 (log cfu/ul.h)
S pneumoniae 136P aeruginosa > 1000
![Page 35: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/35.jpg)
35
CONCLUSION ON MAGNITUDE OF pK/pD PARAMETER
- not uniform across models or species
- models need to be calibrated on the basis of good clinical studies
![Page 36: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/36.jpg)
36
EMERGENCE OF RESISTANCE - THE STORY SO FAR
enoxacin ~ P. aeruginosa
emergence of resistance observed, related to time ofexposure, and total exposure (Cm/MIC)
Blaser et al, 87
Ciprofloxacin ~ P. aeruginosa
dose fractionation (1200 OD; 600BD; 400TDS)1200 OD less resistance than 600 BD or 400 TDS
Marchbanks et al, 1993
![Page 37: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/37.jpg)
37
Ciprofloxacin/ofloxacin ~ P. aeruginosa
AUC/MIC or Cmax/MIC related to emergence ofresistance (MIC )
Madaras-Kelly et al, 1996
![Page 38: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/38.jpg)
38
End points
• MIC before and after exposure
• subculture onto recovery with increasing FQconcentrations (MIC x 0.5; MIC x 1; MIC x 2 etc)
- absolute count on plates- heterogencity of population- area-under-curve - population-analysis-
profile (AUC-PAP)
![Page 39: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/39.jpg)
39
Log cfu/ml
0 Antibiotic concentration
time 0
time 48
time 24
AUC - PAPo
![Page 40: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/40.jpg)
40
EMERGENCE OF RESISTANCE TO MOXIFLOXACINWITH S. PNEUMONIAE & P. AERUGINOSA
P. aeruginosa MIC 0.25mg/L
log cfu/ml 0hr 24hr 72hr
conc in 200 400 400 800 200 400 400 800recovery OD OD BD OD OD OD BD ODplate
0 8.5 8.3 7.6 7.5 7.5 8.3 8.2 7.6 7.5 4 4.7 8.0 7.3 2.6 3.5 8.0 8.2 4.0 4.016 <2 ND 3.4 <2 <2 ND 8.3 3.2 3.5
![Page 41: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/41.jpg)
41
AUC72/MIC for 50% effect -
S. pneumoniae P. aeruginosa
ABE: AUBKC72 136 >1000
Resistancelog cfu/ml MIC x 4 < 50 862log cfu/ml MIC x 16 < 50 1186PAP ~ AUC < 50 910
![Page 42: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/42.jpg)
42
Emergence of resistance depends on
(i) species (P. aeruginosa > S pneumoniae)
(ii) duration of exposure (long > short)
(iii) exposure (large AUC/MIC > small)
(iv) AUC/MIC Cm/MIC
(v) pD parameter magnitude different to effect
![Page 43: Developments in pK/pD: optimising efficacy & prevention of resistance](https://reader036.vdocuments.mx/reader036/viewer/2022062304/56814590550346895db28063/html5/thumbnails/43.jpg)
43
Conclusions
• in vitro models have a vital role in pDassessments
• in vitro models are flexible tools to assess manypD questions, i.e. dosing
• in vitro models can be used for hypothesis testing and generation
• for best value they should compare with animaldata but much important, human data